An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART

Trial Profile

An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Romidepsin (Primary) ; Vacc-4x (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REDUC
  • Sponsors Bionor Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2017 According to a Bionor Pharma media release, results from the study have been presented in a poster presentation at the10th Conference on Global Health and Vaccination Research (GLOBVAC).
    • 11 Jan 2017 Time frame of primary end point of Part A has been changed from 12 weeks to 3 weeks. and time frame of Part B has changed from Week 41 to Day 161/175.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top